Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Due out this spring. PC demo now available. Dark forces are drawn to the lands of Terrinoth. Yet somewhere lies a forgotten relic that could turn the tides. Such power cannot fall into the wrong hands ...

Terrinoth: Heroes Of Descent is a high fantasy tactical RPG that brings the legendary Descent tabletop universe as a video game for the first time. Terrinoth: Heroes Of Descent combines real-time ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, the leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of a fully integrated immune repertoire and ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...